154 related articles for article (PubMed ID: 27783106)
1. Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma.
Adams HJA; Kwee TC
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):342-343. PubMed ID: 27783106
[No Abstract] [Full Text] [Related]
2. Reply to letter of Adams and Kwee: Critical considerations on the predictive value of end-of-treatment FDG/PET in lymphoma.
Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji JB
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):344-345. PubMed ID: 27796542
[No Abstract] [Full Text] [Related]
3. The role of FDG PET in the management of lymphoma: practical guidelines.
Kirby AM; George Mikhaeel N
Nucl Med Commun; 2007 May; 28(5):355-7. PubMed ID: 17414884
[TBL] [Abstract][Full Text] [Related]
4. The role of FDG PET in the management of lymphoma: what is the evidence base?
Kirby AM; Mikhaeel NG
Nucl Med Commun; 2007 May; 28(5):335-54. PubMed ID: 17414883
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
[TBL] [Abstract][Full Text] [Related]
6. PET-Derived Quantitative Metrics for Response and Prognosis in Lymphoma.
Kostakoglu L; Chauvie S
PET Clin; 2019 Jul; 14(3):317-329. PubMed ID: 31084772
[TBL] [Abstract][Full Text] [Related]
7. PET imaging for response assessment in lymphoma: potential and limitations.
Schöder H; Moskowitz C
Radiol Clin North Am; 2008 Mar; 46(2):225-41, viii. PubMed ID: 18619378
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of therapy for lymphoma.
Jerusalem G; Hustinx R; Beguin Y; Fillet G
Semin Nucl Med; 2005 Jul; 35(3):186-96. PubMed ID: 16098292
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
[TBL] [Abstract][Full Text] [Related]
10. PET/CT: appropriate application in lymphoma.
Wang X
Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
[TBL] [Abstract][Full Text] [Related]
11. The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment.
Bombardieri E
Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):753-8. PubMed ID: 16733687
[No Abstract] [Full Text] [Related]
12. Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study.
Fruchart C; Reman O; Le Stang N; Musafiri D; Cheze S; Macro M; Switsers O; Aide N; Liegard M; Levaltier X; Peny AM; Leporrier M; Bardet S
Leuk Lymphoma; 2006 Dec; 47(12):2547-57. PubMed ID: 17169799
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET interpretation in tonsillar lymphoma.
Hsu CH; Lee TJ; Lee FP; Lee CM; Lin YH; Yang CM
Acta Otolaryngol; 2007 Oct; 127(10):1118-20. PubMed ID: 17851897
[No Abstract] [Full Text] [Related]
14. Overview of early response assessment in lymphoma with FDG-PET.
MacManus MP; Seymour JF; Hicks RJ
Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
[TBL] [Abstract][Full Text] [Related]
15. Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma.
Wright CL; Maly JJ; Zhang J; Knopp MV
PET Clin; 2017 Jan; 12(1):63-82. PubMed ID: 27863567
[TBL] [Abstract][Full Text] [Related]
16. When should FDG-PET be used in the modern management of lymphoma?
Barrington SF; Mikhaeel NG
Br J Haematol; 2014 Feb; 164(3):315-28. PubMed ID: 24131306
[TBL] [Abstract][Full Text] [Related]
17. The value of F-18 FDG triple-head coincidence PET in the posttreatment evaluation of patients with lymphoma.
Huić D; Mutvar A; Radman I; Grosev D; Labar B; Zuvić M; Dodig D; Aurer I; Nemet D
Clin Nucl Med; 2006 May; 31(5):275-8. PubMed ID: 16622336
[No Abstract] [Full Text] [Related]
18. The evolving role of fluorodeoxyglucose positron emission tomography (FDG PET) in lymphoma: how do we reconcile conflicting results in the era of evidence-based medicine?
Hicks RJ
Leuk Lymphoma; 2006 Oct; 47(10):2008-10. PubMed ID: 17071468
[No Abstract] [Full Text] [Related]
19. Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma.
Goudarzi B; Jacene HA; Wahl RL
Acad Radiol; 2010 Sep; 17(9):1175-85. PubMed ID: 20634105
[TBL] [Abstract][Full Text] [Related]
20. Evolving Role of PET-Based Novel Quantitative Techniques in the Management of Hematological Malignancies.
Raynor WY; Zadeh MZ; Kothekar E; Yellanki DP; Alavi A
PET Clin; 2019 Jul; 14(3):331-340. PubMed ID: 31084773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
